The regulatory effect of ripk1-ripk3 on necroptosis and neuroinflammation in acute ischemic stroke patients and patients with thrombolytic therapy

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100046488

Enrollment

Unknown

Registered

2021-05-16

Start date

2021-06-01

Completion date

Unknown

Last updated

2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

acute ischemic stroke group vs. healthy control group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Enrollment criteria included subjects presenting with acute cerebral vascular ischemia.

Exclusion criteria

Exclusion criteria: 1. Acute inflammatory diseases: hepatitis, pneumonia, HIV, etc.; 2. Autoimmune diseases: systemic lupus erythematosus, sjogren's syndrome; 3. Tumor is not excluded; 4. Recently treated with antibiotics; 5. Recent use of glucocorticoids.

Design outcomes

Primary

Measure	Time frame
RIPK1;	—

Countries

China

Contacts

Public ContactLi Miaodan

Zengcheng Branch of Southern Hospital

limiaodan90@163.com+86 18819134327

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026